Halozyme Therapeutics Stock News

GILD vs. HALO: Which Stock Is the Better Value Option?

Halozyme's under-the-skin technology helps deliver some of the biggest moneymaking injections, fueling booming growth and prospects for much more. HALO stock is surging.

S&P 500 is breathing a much-awaited sigh of relief after the monthly inflation data came in better than expected (read more). But there's hardly a reason to believe that it's not just another one of t

Halozyme's (HALO) earnings and revenues beat estimates for the third quarter of 2022.

Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations & Corporate Communication Hel

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 42.31% and 11.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the sto

Halozyme Therapeutics (HALO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Halozyme made a smooth transition from a failed R&D company to a successful royalty company. Their Antares acquisition is a bid to delay ENHANZE IP expiry, although the autoinjector platform is no rea

The new Halozyme is well-fixed to grow revenues from multiple sources over the balance of this decade and beyond. Halozyme's effective execution of its business model substantially reduces its risk pr

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?

Halozyme's (HALO) second-quarter earnings and sales beat estimates. Following the completion of the acquisition of Antares Pharma, the company raises its financial guidance for 2022.

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 6% and 15.41%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations & Corporate Communication Helen

Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the

Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the